|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schabath MB, Nguyen A, Wilson P, Sommerer
KR, Thompson ZJ and Chiappori AA: Temporal trends from 1986 to 2008
in overall survival of small cell lung cancer patients. Lung
Cancer. 86:14–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Uramoto H and Tanaka F: Recurrence after
surgery in patients with NSCLC. Transl Lung Cancer Res. 3:242–249.
2014.PubMed/NCBI
|
|
4
|
Li C and Hong W: Research status and
funding trends of lung cancer biomarkers. J Thorac Dis. 5:698–705.
2013.PubMed/NCBI
|
|
5
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Skrzypski M, Dziadziuszko R and Jassem J:
MicroRNA in lung cancer diagnostics and treatment. Mutat Res.
717:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boeri M, Sestini S, Fortunato O, Verri C,
Suatoni P, Pastorino U and Sozzi G: Recent advances of
microRNA-based molecular diagnostics to reduce false-positive lung
cancer imaging. Expert Rev Mol Diagn. 15:801–813. 2015.PubMed/NCBI
|
|
12
|
Guan P, Yin Z, Li X, Wu W and Zhou B:
Meta-analysis of human lung cancer microRNA expression profiling
studies comparing cancer tissues with normal tissues. J Exp Clin
Cancer Res. 31:542012.doi: 10.1186/1756-9966-31-54. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu
X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis
of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A).
Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jia YY, Zhao JY, Li BL, Gao K, Song Y, Liu
MY, Yang XJ, Xue Y, Wen AD and Shi L: miR-592/WSB1/HIF-1α axis
inhibits glycolytic metabolism to decrease hepatocellular carcinoma
growth. Oncotarget. 7:35257–35269. 2016.PubMed/NCBI
|
|
15
|
Li X, Zhang W, Zhou L, Yue D and Su X:
MicroRNA-592 targets DEK oncogene and suppresses cell growth in the
hepatocellular carcinoma cell line HepG2. Int J Clin Exp Pathol.
8:12455–12463. 2015.PubMed/NCBI
|
|
16
|
Liu M, Zhi Q, Wang W, Zhang Q, Fang T and
Ma Q: Up-regulation of miR-592 correlates with tumor progression
and poor prognosis in patients with colorectal cancer. Biomed
Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Wu R, Li G, Sun P, Xu Q and Liu Z:
MiR-592 inhibited cell proliferation of human colorectal cancer
cells by suppressing of CCND3 expression. Int J Clin Exp Med.
8:3490–3497. 2015.PubMed/NCBI
|
|
18
|
Lv Z, Rao P and Li W: MiR-592 represses
FOXO3 expression and promotes the proliferation of prostate cancer
cells. Int J Clin Exp Med. 8:15246–15253. 2015.PubMed/NCBI
|
|
19
|
Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y,
Li Y, Wu Q and Deng Y: Integrative microRNA and gene profiling data
analysis reveals novel biomarkers and mechanisms for lung cancer.
Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
|
|
20
|
Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu
XY and Gong LY: Clinical significance of SOX9 in human non-small
cell lung cancer progression and overall patient survival. J Exp
Clin Cancer Res. 31:182012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chaboissier MC, Kobayashi A, Vidal VI,
Lützkendorf S, van de Kant HJ, Wegner M, de Rooij DG, Behringer RR
and Schedl A: Functional analysis of Sox8 and Sox9 during sex
determination in the mouse. Development. 131:1891–1901. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akiyama H, Chaboissier MC, Martin JF,
Schedl A and de Crombrugghe B: The transcription factor Sox9 has
essential roles in successive steps of the chondrocyte
differentiation pathway and is required for expression of Sox5 and
Sox6. Genes Dev. 16:2813–2828. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Müller P, Crofts JD, Newman BS,
Bridgewater LC, Lin CY, Gustafsson JA and Ström A: SOX9 mediates
the retinoic acid-induced HES-1 gene expression in human breast
cancer cells. Breast Cancer Res Treat. 120:317–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E,
Huang Q and Lai M: Analysis of SOX9 expression in colorectal
cancer. Am J Clin Pathol. 130:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Leav I, Ibaragi S, Wegner M, Hu
GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal
prostate epithelium and enhances prostate cancer invasion. Cancer
Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seymour PA: Sox9: A master regulator of
the pancreatic program. Rev Diabet Stud. 11:51–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang SS, Fang WT, Hou YH, Huang SF, Yen
BL, Chang JL, Li SM, Liu HP, Liu YL, Huang CT, et al: Upregulation
of SOX9 in lung adenocarcinoma and its involvement in the
regulation of cell growth and tumorigenicity. Clin Cancer Res.
16:4363–4373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Ju Y, Zhou MI, Liu X and Zhou C:
Upregulation of SOX9 promotes cell proliferation, migration and
invasion in lung adenocarcinoma. Oncol Lett. 10:990–994.
2015.PubMed/NCBI
|
|
29
|
Capaccione KM, Hong X, Morgan KM, Liu W,
Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, et
al: Sox9 mediates Notch1-induced mesenchymal features in lung
adenocarcinoma. Oncotarget. 5:3636–3650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Liu Y, Liu X, Yang J, Teng G,
Zhang L and Zhou C: MiR-124 inhibits cell proliferation, migration
and invasion by directly targeting SOX9 in lung adenocarcinoma.
Oncol Rep. 35:3115–3121. 2016.PubMed/NCBI
|
|
31
|
Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC
and Li L: miR-206 inhibits non small cell lung cancer cell
proliferation and invasion by targeting SOX9. Int J Clin Exp Med.
8:9107–9113. 2015.PubMed/NCBI
|
|
32
|
Zhu D, Chen H, Yang X, Chen W, Wang L, Xu
J and Yu L: miR-32 functions as a tumor suppressor and directly
targets SOX9 in human non-small cell lung cancer. Onco Targets
Ther. 8:1773–1783. 2015. View Article : Google Scholar : PubMed/NCBI
|
